Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P -Values
The Oncologist · 02.02.2024 · 29 (2) · 102-105
DOI: 10.1093/oncolo/oyad203 ↗Kurz gefasst
Editorial in der Zeitschrift The Oncologist, online erschienen am 08.09.2023. Verfasst von Antonio Tito Fojo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New Y…. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
This article continues the discussion on the results of the BILCAP trial and advocates for careful examination and consideration of data in its entirety to inform a clinician’s decision.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Zitieren
APA
Fojo, A. T., & Neugut, A. I. (2024). Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P -Values. The Oncologist, 29(2), 102-105. https://doi.org/10.1093/oncolo/oyad203
Vancouver
Fojo AT, Neugut AI. Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P -Values. The Oncologist. 2024;29(2):102-105. doi:10.1093/oncolo/oyad203
BibTeX
@article{Fojo2024,
author = {Fojo, Antonio Tito and Neugut, Alfred I},
title = {Adjuvant Capecitabine for Biliary Cancer and the Importance of Looking Beyond P -Values},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {2},
pages = {102--105},
doi = {10.1093/oncolo/oyad203}
}
EUVIMED